Cargando…
The design and evaluation of hybrid controlled trials that leverage external data and randomization
Patient-level data from completed clinical studies or electronic health records can be used in the design and analysis of clinical trials. However, these external data can bias the evaluation of the experimental treatment when the statistical design does not appropriately account for potential confo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527257/ https://www.ncbi.nlm.nih.gov/pubmed/36184621 http://dx.doi.org/10.1038/s41467-022-33192-1 |
_version_ | 1784801045331836928 |
---|---|
author | Ventz, Steffen Khozin, Sean Louv, Bill Sands, Jacob Wen, Patrick Y. Rahman, Rifaquat Comment, Leah Alexander, Brian M. Trippa, Lorenzo |
author_facet | Ventz, Steffen Khozin, Sean Louv, Bill Sands, Jacob Wen, Patrick Y. Rahman, Rifaquat Comment, Leah Alexander, Brian M. Trippa, Lorenzo |
author_sort | Ventz, Steffen |
collection | PubMed |
description | Patient-level data from completed clinical studies or electronic health records can be used in the design and analysis of clinical trials. However, these external data can bias the evaluation of the experimental treatment when the statistical design does not appropriately account for potential confounders. In this work, we introduce a hybrid clinical trial design that combines the use of external control datasets and randomization to experimental and control arms, with the aim of producing efficient inference on the experimental treatment effects. Our analysis of the hybrid trial design includes scenarios where the distributions of measured and unmeasured prognostic patient characteristics differ across studies. Using simulations and datasets from clinical studies in extensive-stage small cell lung cancer and glioblastoma, we illustrate the potential advantages of hybrid trial designs compared to externally controlled trials and randomized trial designs. |
format | Online Article Text |
id | pubmed-9527257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95272572022-10-04 The design and evaluation of hybrid controlled trials that leverage external data and randomization Ventz, Steffen Khozin, Sean Louv, Bill Sands, Jacob Wen, Patrick Y. Rahman, Rifaquat Comment, Leah Alexander, Brian M. Trippa, Lorenzo Nat Commun Article Patient-level data from completed clinical studies or electronic health records can be used in the design and analysis of clinical trials. However, these external data can bias the evaluation of the experimental treatment when the statistical design does not appropriately account for potential confounders. In this work, we introduce a hybrid clinical trial design that combines the use of external control datasets and randomization to experimental and control arms, with the aim of producing efficient inference on the experimental treatment effects. Our analysis of the hybrid trial design includes scenarios where the distributions of measured and unmeasured prognostic patient characteristics differ across studies. Using simulations and datasets from clinical studies in extensive-stage small cell lung cancer and glioblastoma, we illustrate the potential advantages of hybrid trial designs compared to externally controlled trials and randomized trial designs. Nature Publishing Group UK 2022-10-02 /pmc/articles/PMC9527257/ /pubmed/36184621 http://dx.doi.org/10.1038/s41467-022-33192-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ventz, Steffen Khozin, Sean Louv, Bill Sands, Jacob Wen, Patrick Y. Rahman, Rifaquat Comment, Leah Alexander, Brian M. Trippa, Lorenzo The design and evaluation of hybrid controlled trials that leverage external data and randomization |
title | The design and evaluation of hybrid controlled trials that leverage external data and randomization |
title_full | The design and evaluation of hybrid controlled trials that leverage external data and randomization |
title_fullStr | The design and evaluation of hybrid controlled trials that leverage external data and randomization |
title_full_unstemmed | The design and evaluation of hybrid controlled trials that leverage external data and randomization |
title_short | The design and evaluation of hybrid controlled trials that leverage external data and randomization |
title_sort | design and evaluation of hybrid controlled trials that leverage external data and randomization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527257/ https://www.ncbi.nlm.nih.gov/pubmed/36184621 http://dx.doi.org/10.1038/s41467-022-33192-1 |
work_keys_str_mv | AT ventzsteffen thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT khozinsean thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT louvbill thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT sandsjacob thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT wenpatricky thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT rahmanrifaquat thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT commentleah thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT alexanderbrianm thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT trippalorenzo thedesignandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT ventzsteffen designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT khozinsean designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT louvbill designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT sandsjacob designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT wenpatricky designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT rahmanrifaquat designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT commentleah designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT alexanderbrianm designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization AT trippalorenzo designandevaluationofhybridcontrolledtrialsthatleverageexternaldataandrandomization |